Navigate Shifting Reimbursement Criteria for Molecular Testing
At TELCOR, we’ve recently identified a notable shift in how molecular claims specifically associated with CPT code 87798, are being processed by...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
Quality Payment Program Claim Adjustment Applied to Correct Conversion Factor
The Centers for Medicare & Medicaid Services has found a system issue related to the 2026 Medicare Physician Fee Schedule conversion factors.
Updated CDLT Data Reporting Period to Begin May 1
Effective May 1, clinical diagnostic laboratories will be required to follow new data reporting requirements for clinical diagnostic laboratory tests...